Daxor Corporation has received FDA 510(k) clearance for its latest hand-held, laboratory-based Blood Volume Analyser (BVA).
The patent-pending device is designed to provide rapid and precise measurement of a patient’s blood volume compared with individual norms, supporting better fluid management across a wide range of medical conditions.
Accurate assessment of blood volume is critical in the treatment of conditions such as heart failure, sepsis, kidney disease, trauma, and surgical recovery.
Until now, clinicians have often relied on indirect or invasive methods, which can be less accurate. Daxor’s new system aims to close this gap by delivering faster and more reliable data in both hospital and outpatient settings.
Fluid imbalance is a major cause of hospital admissions and complications, contributing to a significant financial burden on healthcare systems each year.
Studies have shown that the use of blood volume analysis can lead to major improvements in outcomes, including reduced mortality, shorter hospital stays, fewer readmissions, and lower overall costs.
Research in patients with heart failure reported an 86% reduction in one-year mortality, while trials in intensive care units demonstrated a 66% reduction in mortality for patients with sepsis or acute respiratory distress.
The new analyser builds on the company’s earlier BVA-100™ system and introduces several key improvements. It delivers results three times faster than before, remains lightweight at only 7 lbs, and maintains laboratory-grade accuracy.
Daxor’s technology has been validated in collaboration with leading institutions including Duke University Medical Center, Cleveland Clinic, Mayo Clinic, and the U.S. Department of Veterans Affairs. With over 75,000 tests already in use and more than five decades of research, the company continues to expand the role of precision diagnostics in clinical care.
